Nimotuzumab, an Anti-EGFR Monoclonal Antibody, in the Treatment of Nasopharyngeal Carcinoma
Renba Liang, Yang Liu, Xiaodong Zhu
Abstract
Epidermal growth factor receptor (EGFR) is highly expressed in most of Nasopharyngeal carcinoma (NPC) samples and is associated with poor outcomes. Therefore, targeting EGFR may be a promising strategy to improve patient prognosis. Nimotuzumab is a humanized anti-EGFR monoclonal antibody. Recently, accumulating evidence has demonstrated that combination nimotuzumab and induction chemotherapy, radiotherapy, or concurrent chemoradiotherapy confer benefits for patients with NPC. Moreover, the side effects of such regimes are tolerable. In this review, we focus on the current data of nimotuzumab in clinical trials in the treatment of NPC.
Topics & Concepts
NimotuzumabMedicineNasopharyngeal carcinomaMonoclonal antibodyEpidermal growth factor receptorOncologyChemoradiotherapyRadiation therapyMonoclonalInternal medicineCarcinomaCancer researchAntibodyImmunologyReceptorHead and Neck Cancer StudiesLung Cancer Treatments and MutationsLung Cancer Research Studies